https://www.globenewswire.com/news-release/2024/04/04/2857599/0/en/Achilles-Therapeutics-Provides-Interim-Phase-I-IIa-Update-on-Clonal-Neoantigen-Reactive-T-Cells-in-Advanced-NSCLC-and-Melanoma-Including-First-Patients-Dosed-with-Enhanced-Host-Con.html
Slides https://ir.achillestx.com/static-files/d1f75ff0-b8d4-4b0c-8827-0931e5b91e70
Recent ACHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 11:00:27 AM
- Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines • GlobeNewswire Inc. • 05/22/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 09:15:57 PM
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement • GlobeNewswire Inc. • 05/17/2024 09:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:44:20 AM
- Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 04/04/2024 10:45:00 AM
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning • GlobeNewswire Inc. • 04/04/2024 10:30:00 AM
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 06:14:13 PM
- Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction • GlobeNewswire Inc. • 12/18/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 09:36:37 PM
- Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/13/2023 09:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/01/2023 09:26:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/22/2023 08:42:59 PM
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement • GlobeNewswire Inc. • 09/22/2023 08:30:00 PM
- Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation • InvestorsHub NewsWire • 09/20/2023 12:45:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/17/2023 07:16:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/04/2023 11:42:07 AM
- Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 08/04/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/29/2023 08:03:49 PM
- Achilles Therapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 06/12/2023 12:00:00 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM